335654-08-5

Basic information

• Product Name: 2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one
• Synonyms: 2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;2-Chloro-5,7-dihydro-6H-p...;2-chloro-5H,6H,7H-pyrrolo[2,3-d]pyriMidin-6-one;2-chloro-1H-pyrrolo[2,3-d]pyrimidin-6(5H)-one;2-Chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H);2-chloro-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one
• CAS NO: 335654-08-5
• Molecular Formula: C₆H₄ClN₃O
• Molecular Weight: 169.57
• Product Categories: CHIRAL CHEMICALS
• Mol File: 335654-08-5.mol

Chemical Properties

• Boiling Point: 479.5 °C at 760 mmHg
• Flash Point: 243.8 °C
• Appearance: /
• Density: 1.549 g/cm³
• Vapor Pressure: 2.35E-09mmHg at 25°C
• Refractive Index: 1.618
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.24±0.20(Predicted)
• CAS DataBase Reference: 2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one(335654-08-5)
• EPA Substance Registry System: 2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one(335654-08-5)

Safety Data

• Hazardous Substances Data: 335654-08-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one is used as a key intermediate in the synthesis of new drugs for various therapeutic applications. Its structural resemblance to purine bases enables it to modulate biological processes and target specific pathways, making it a valuable component in drug discovery and development.
Used in Chemical Manufacturing:
2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one is used as a building block in the manufacturing of specialty chemicals. Its unique chemical properties and reactivity make it suitable for the production of various chemical compounds with specific functionalities and applications.
Used in Research and Development:
2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one serves as a research tool in the study of nucleic acids and nucleotides. Its interaction with biological systems and its structural features make it an important compound for understanding the mechanisms of action and potential applications in molecular biology and related fields.

InChI:InChI=1/C6H4ClN3O/c7-6-8-2-3-1-4(11)9-5(3)10-6/h2H,1H2,(H,8,9,10,11)

Upstream product

• 335654-13-2 2-chloro-5-(2,2-dimethoxy-ethyl)-pyrimidin-4-ylamine 
• 335654-05-2 2-chloro-5-(2-ethoxyvinyl)pyrimidin-4-amine 
• 335654-06-3 2-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 335654-07-4 5,5-dibromo-2-chloro-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one 

Downstream Products

• 5817-96-9 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1360822-16-7 E/Z-2-chloro-5-(3-chloro-2-fluorobenzylidene)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one 

Relevant articles and documents

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS

Novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

Indolin-2-one p38α inhibitors II: Lead optimisation

Optimisation of a series of indolin-2-one p38α inhibitors was achieved via both blocking of a potential metabolic 'hot spot' and by increasing overall polarity of the lead series leading to non-cytotoxic compounds which showed improved oral bioavailabilities in the rat.

New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

Synthesis of 2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one

1,3-Dihydro-2H-indol-2-ones (oxindoles) and 1,3-dihydro-2H-pyrrolopyridin-2-ones (azaoxindoles) are useful scaffolds that have been explored for various pharmaceutical uses. Herein we report the synthesis of 2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin